Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL1205
- Development stage
- Phase 1
- Lead developer
- Qilu Pharmaceutical
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
QL1205 is a biosimilar to ranibizumab, developed by Qilu Pharmaceutical. It is a recombinant, humanized monoclonal antibody fragment (Fab) that binds to and inhibits vascular endothelial growth factor A (VEGF-A), thereby suppressing abnormal blood vessel growth and leakage in the eye. The drug is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD). Clinical trials have demonstrated that QL1205 has equivalent efficacy, safety, pharmacokinetics, and immunogenicity compared to reference ranibizumab (Lucentis), supporting its use as a cost-effective alternative for anti-VEGF therapy in ophthalmology[1][2][4].
- Brand names
- QL1205QL-1205QL 1205
- Other names
- ranibizumab biosimilar QL1205Qilu ranibizumab biosimilar
02
Targets
Beyond the preview
Go deeper on QL1205.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL1205.